Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
16/06/2026 02:42
BRIEF-Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia June 16 (Reuters) - Everest Medicines Ltd 1952.HK:
AGREEMENT WITH DIMERIX TO DEVELOP COMMERCIALIZE DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA
DEAL INCLUDES $10 MILLION UPFRONT, UP TO $30 MILLION DEVELOPMENT MILESTONES, $300 MILLION SALES MILESTONES, 10%-15% ROYALTIES
DMX-200 RECEIVES ORPHAN DRUG DESIGNATIONS FROM FDA AND EMA
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region